Compare LITE & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITE | REGN |
|---|---|---|
| Founded | 2015 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.9B | 84.3B |
| IPO Year | 2015 | 1995 |
| Metric | LITE | REGN |
|---|---|---|
| Price | $527.79 | $916.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 28 |
| Target Price | ★ $1,110.07 | $977.93 |
| AVG Volume (30 Days) | ★ 5.1M | 818.9K |
| Earning Date | 11-02-2026 | 10-30-2026 |
| Dividend Yield | N/A | ★ 0.40% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | 3.54 | ★ 37.37 |
| Revenue | $1,247,700,000.00 | ★ $5,872,227,000.00 |
| Revenue This Year | $121.98 | $22.74 |
| Revenue Next Year | $49.24 | $14.18 |
| P/E Ratio | $177.07 | ★ $24.91 |
| Revenue Growth | ★ 24.57 | 20.82 |
| 52 Week Low | $215.35 | $591.52 |
| 52 Week High | $1,143.00 | $991.73 |
| Indicator | LITE | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 31.68 | 69.83 |
| Support Level | $561.20 | $736.27 |
| Resistance Level | $972.47 | N/A |
| Average True Range (ATR) | 64.37 | 29.35 |
| MACD | -23.52 | 18.05 |
| Stochastic Oscillator | 7.41 | 71.05 |
Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.